Sotirios Tsimikas MD, FACC, FAHA, FSCAI

Dr. Tsimikas is Professor of Medicine and Director of Vascular Medicine at the University of California San Diego School of Medicine. He obtained his MD degree from the University of Massachusetts Medical School in 1988, completed Internal Medicine training at the University of Massachusetts Medical Center in 1991, and fellowships in Cardiovascular Disease, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego from 1992-1997. He is fellow of the American College of Cardiology, American Heart Association and Society of angiography and Intervention. Dr. Tsimikas clinical interests are in Interventional Cardiology and in lipid disorders, particularly in Lp(a). In 2014, he established the world’s first dedicated “Lp(a) Clinic”. He teaches on atherosclerosis to UCSD Medical students. His research interests focus on: 1-“biotheranostics”- biomarkers, molecular imaging and therapeutics targeted to oxidation-specific epitopes; and 2-Lp(a) pathophysiology and therapeutics. He is co-inventor and developer of the OxPL-apoB assay, which is the focus of 53 original scientific publications and 25 review articles. He has spearheaded clinical development and clinical trials of several antisense oligonucleotides, including to apoC-III, Lp(a), ANGPTL3, and angiotensinogen, one of which is approved in Europe and others are in phase 2-3 trials. He has published in all of the major medical journals, including NEJM, Lancet, Nature, Cell, JACC, Circulation, Circulation Research, European Heart Journal, ATVB, JAMA Cardiology and has published over 280 original manuscripts, review articles and book chapters. His works have been cited over 11,900 times and he has an H-index of 63.